The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...
Celltrion launches ADC cancer drug trials in U.S. while planning additional INDs Celltrion accelerates its global drug ...
Celltrions Vegzelma becomes Europes top prescribed anticancer drug in two years Celltrions cancer treatment Vegzelma achieves impressive market dominance in Europe within two years ...
As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...
The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.
Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...
US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...
On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...
The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated ...
The US Food and Drug Administration (FDA) has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to Actemra, developed by South ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback